New Zealand: A budding industry for cannabis products in New Zealand

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

New Zealand: A budding industry for cannabis products in New Zealand

Sponsored by

aj-park.png
Green background of leaves. Young cannabis plant. Cannabis at the beginning of flowering. Northern light strain. Medicinal indica with CBD. In door grow hemp. moody color

In September 2020, New Zealanders will participate in a non-binding cannabis referendum on the question of whether to legalise the use and supply of cannabis. New Zealanders will be given the option of voting either for or against the proposed Cannabis Legalisation and Control Bill (the Bill). The final version of the Bill, which was released in May 2020, legalises the use of cannabis for persons over the age of 20, but places severe restrictions around the promotion and packaging of cannabis products.


Medicinal cannabis

In New Zealand, the use of cannabis for medicinal purposes is legal, and licensed commercial cultivation and manufacture of medicinal cannabis is permitted.

Trademarks covering medicinal cannabis can be registered with the Intellectual Property Office of New Zealand (IPONZ), provided the specifications are restricted to Class 5 (pharmaceutical products). If the trademark contains elements indicating that the goods are medicinal cannabis, but covers goods in other classes, IPONZ will raise a Section 17(1)(a) Trade Marks Act 2002 (TMA) "likely to cause confusion" objection against the application.

Acceptable descriptions in Class 5 would include "medicinal cannabis oil; medicinal cannabis balm; medicinal cannabis cookies." Trademark owners should take note of this policy, and cover all relevant medicinal cannabis products in Class 5, regardless of whether these products are in capsule, oil, or edible form.


Recreational cannabis

In New Zealand, the Misuse of Drugs Act 1975 prohibits the use and supply of recreational cannabis.

Trademarks covering recreational cannabis can nevertheless be registered with IPONZ. Article (15)4 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which New Zealand has ratified, provides that "the nature of the goods or services to which a trade mark is to be applied shall in no case form an obstacle to registration of the trade mark."

Consequently, IPONZ should not raise a Section 17(1)(b) TMA "contrary to law" objection to a trademark application covering recreational cannabis, and the application should proceed to registration if there are no other issues.

Trademark owners should note, however, that if a trademark is not used for a continuous three-year period, it may become vulnerable to revocation for non-use. Although a trademark owner in New Zealand can successfully defend a non-use action by showing "special circumstances that are outside the control of the owner" under Section 66(2) of the TMA, it is unlikely that the prohibition against the use and supply of recreational cannabis will qualify as "special circumstances."

Those who register trademarks for recreational cannabis before the Bill passes are therefore at risk of having their registrations revoked for non-use.


The proposed Cannabis Legalisation and Control Bill

As part of its harm prevention approach, the proposed Bill places severe restrictions on the promotion of recreational cannabis products and imposes strict packaging standards.

The Bill also places limitations on the use of cannabis product trademarks. In particular, the Bill prohibits cannabis product trademarks from being:


  • promoted or advertised;

  • displayed outside a retailer's place of business;

  • used on non-cannabis products; or

  • used in relation to services, activities, events, scholarships and sponsorships.

In addition, the Bill gives the governor-general the power to make regulations prescribing the appearance of packaging for cannabis products, including the font, size, and colour scheme of cannabis product trademarks. These regulations are likely to be similar to the Smoke-Free Environment Regulations, which prescribe a standard font and size for tobacco product trademarks.


Key takeaways

If there is a majority yes vote in New Zealand's upcoming cannabis referendum, and the proposed Bill passes, New Zealand's trademark landscape will change.

Trademark applicants looking to register and use cannabis product trademarks in New Zealand should note that the font, size and colour of their trademarks are likely to be governed by strict regulations, and that they will be prohibited from advertising and promoting their trademarks in the New Zealand market.

more from across site and SHARED ros bottom lb

More from across our site

The firm is shaping its AI strategy around partnerships with Harvey and Legora alongside internally developed tools from its legal technology company, ELTEMATE
A dispute Down Under shows why trademark lawyers cannot afford to wait on the sidelines when a rival brand gathers momentum
The Third Circuit’s decision in Thomson Reuters v ROSS marks the first appellate-level decision addressing AI and fair use, prompting copyright counsel to consider arguments around potential licensing markets
Injunctions for HandsFree Labs and Align Technology come as the Court of Appeal warns that busy teams must have the staffing and resources to meet UPC deadlines
The chief technology officer remit, which has been created as the firm is building its litigation team, will include expanding the use of AI in patent and legal work and automating manual processes
Former Hoyng Rokh Moneiger partner Laura Alonso, who brought her team to ECIJA in March, discusses plans to expand further and why ECIJA’s ‘IP DNA’ is helping broaden her work
Amita Haylock discusses building an integrated Asia practice as clients increasingly demand that firms combine IP, technology and data expertise
François Pochart, Grégoire Desrousseaux and Lionel Martin, long-standing figures in the firm’s patent litigation team, are set to help launch a Paris-based litigation offering
The Unitary Patent has passed 100,000 registrations, but new data raises the question of whether 30% uptake is a ceiling or a staging post for further growth, say Michael Nielsen and Darren Smyth of EIP and Andrew Samm at Patently
The new generation of in-house IP leaders want commercial judgment, accessibility and flexibility, with AI raising expectations around both fees and delivery
Gift this article